Tealwood Asset Management Inc. Sells 130 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Tealwood Asset Management Inc. trimmed its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 1.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,638 shares of the medical equipment provider’s stock after selling 130 shares during the quarter. Tealwood Asset Management Inc.’s holdings in Lantheus were worth $952,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in LNTH. Geode Capital Management LLC raised its stake in Lantheus by 2.0% in the third quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock valued at $184,798,000 after purchasing an additional 32,551 shares in the last quarter. Moloney Securities Asset Management LLC bought a new stake in shares of Lantheus during the 3rd quarter worth $1,066,000. Massachusetts Financial Services Co. MA purchased a new position in Lantheus in the third quarter worth $25,955,000. Van ECK Associates Corp increased its stake in Lantheus by 58.6% in the third quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider’s stock valued at $6,469,000 after acquiring an additional 21,604 shares during the last quarter. Finally, Swedbank AB increased its position in shares of Lantheus by 21.1% during the 3rd quarter. Swedbank AB now owns 722,243 shares of the medical equipment provider’s stock valued at $79,266,000 after purchasing an additional 125,843 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors.

Lantheus Trading Down 1.3 %

Shares of LNTH opened at $94.65 on Tuesday. Lantheus Holdings, Inc. has a 1-year low of $50.20 and a 1-year high of $126.89. The firm has a market capitalization of $6.58 billion, a price-to-earnings ratio of 15.75 and a beta of 0.46. The firm’s 50-day moving average price is $90.39 and its 200-day moving average price is $99.69.

Analysts Set New Price Targets

LNTH has been the topic of a number of analyst reports. Truist Financial reiterated a “buy” rating and issued a $120.00 target price (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th. The Goldman Sachs Group started coverage on shares of Lantheus in a report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price target on the stock. JMP Securities lowered their price objective on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a research note on Thursday, November 7th. Finally, StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, Lantheus currently has a consensus rating of “Moderate Buy” and an average target price of $131.86.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.